Ultragenyx logo
  • Patient Advocacy
  • U.S.
    • ARGENTINA
    • BRAZIL
    • CANADA (English)
    • CANADA (Français)
    • CHILE
    • COLOMBIA
    • FRANCE
    • Germany
    • ITALY
    • JAPAN
    • MEXICO
    • PERU
    • SPAIN
    • UNITED KINGDOM
    • UNITED STATES
  • Home
  • Ultra-Committed
        • Ultra committed Mega menu

          To transform the lives of as many people living with rare diseases as possible, we dedicate ourselves every day to the development and delivery of treatments of rare diseases where none currently exist.

        • Ultra-Committed

          Learn more

        • Leadership
        • Access to Our Therapies
        • Early Access
        • Policy Government and Public Affairs
          • Access Resources
        • Corporate Responsibility
        • Grants & Contributions
        • Patient Advocacy
  • Research
        • Latest news Lab

          We develop therapies for rare and ultrarare genetic diseases by exploring an array of drug modalities to select the best treatment strategy for each genetic disease we are studying.

        • Research

          Learn more

        • Our Science
        • Our Gene Therapy Platform
        • Our Pipeline
          • DTX401 for GSDIa
          • DTX301 for OTC Deficiency
          • UX701 for Wilson Disease
          • UX143 for OI
          • GTX-102 for AS
          • UX111 for MPS IIIA
          • UX055 for CDD
        • Our Clinical Trial Transparency Commitment
        • Disease Monitoring Programs
  • Medicines
  • Partnerships
  • Join Our Team
        • Join Our Team Mega Menu

          We have built a talented team and a vibrant, people-first culture. We share a passion for helping those living with rare diseases.

        • Join our team

          Learn More

        • Culture
        • Benefits
        • Current Opportunities
          • Commercial and Medical Affairs
          • Research and Development
          • Technical Operations
          • Corporate Functions
        • Internships, Co-ops & Postdoctoral Programs
        • Contact Us
  • Newsroom
        • Rare Perspective Mega Menu

          Access news releases, presentations, and blog posts to follow the latest developments at Ultragenyx.

        • Newsroom

          Learn More

        • Press Releases
        • Blog
        • Media Asset Library
  • Investors
  • Patient Advocacy
  • U.S.
    • ARGENTINA
    • BRAZIL
    • CANADA (English)
    • CANADA (Français)
    • CHILE
    • COLOMBIA
    • FRANCE
    • Germany
    • ITALY
    • JAPAN
    • MEXICO
    • PERU
    • SPAIN
    • UNITED KINGDOM
    • UNITED STATES
Menu Close

Leader Type: Board of directors

Ultragenyx pharmaceutical logo

Going beyond every day

© 2025 Ultragenyx Pharmaceutical Inc. All rights reserved.
  • PATIENT ADVOCACY
  • CONTACT US
  • PRIVACY POLICY
  • COOKIE POLICY
  • SITE MAP
  • FacebookFB White IconFB Icon Pink
  • LinkedinLinkedInLinkedIn
  • Twitter

This site uses cookies to provide you with a more responsive and personalized service. By clicking “Accept” below, you agree to the use of cookies on this site. Please read our Cookie Policy and Privacy Policy for more information on the use of cookies on this website.

Accept Do not accept